Goal: To evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.
- Phase III, randomized, double-blind, placebo-controlled trial.
- Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29.
- Multicenter trial with 100 centers globally and 1500 subject enrollment goal.
Diego Lopez de Castilla, MD, EvergreenHealth Infectious Disease Care